GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Diabetes, Obesity and Metabolism, Wiley, Vol. 22, No. 4 ( 2020-04), p. 492-500
    Abstract: To investigate the efficacy of adding the glucagon‐like peptide‐1 receptor agonist liraglutide to continuous subcutaneous insulin infusion (CSII) in overweight or obese persons with type 1 diabetes and non‐optimal glycaemic control. Materials and methods A 26‐week, randomized, double‐blind, placebo‐controlled trial including 44 overweight or obese adults with type 1 diabetes randomized 1:1 to liraglutide 1.8 mg once daily (QD) or placebo added to CSII treatment. The primary endpoint was change in haemoglobin A1c (HbA1c). Secondary endpoints included change in insulin dose, CSII settings, glycaemic variability, body weight and patient‐reported outcome measures. Finally, adverse effects including hypoglycaemic events were registered. Results HbA1c was reduced by 5 mmol/mol (0.5%) from a baseline of 66 mmol/mol (8.2%) in patients treated with liraglutide compared with a non‐significant change of +2.3 mmol/mol (0.2%) from a baseline of 66 mmol/mol (8.1%) in patients treated with placebo (between‐group difference 7 mmol/mol [0.7%], P 〈  0.001). Liraglutide reduced total insulin dose by 8 units/day or 16% of total insulin dose ( P = 0.008). Mean body weight was reduced by 6.3 kg ( P 〈  0.001) compared with placebo. Concomitantly, time spent in glycaemic target range 4–10 mmol/L (71–180 mg/dL) increased while the risk of hypoglycaemia did not differ between groups at the end of treatment. Conclusion Liraglutide treatment reduced HbA1c, total daily insulin dose and body weight without increasing the risk of hypoglycaemia in CSII‐treated patients with type 1 diabetes and insufficient glycaemic control. Liraglutide may be considered a potential add‐on therapy to insulin in this subgroup of patients.
    Type of Medium: Online Resource
    ISSN: 1462-8902 , 1463-1326
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2004918-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Diabetes, Obesity and Metabolism, Wiley, Vol. 24, No. 2 ( 2022-02), p. 212-220
    Abstract: To present secondary outcome analyses of liraglutide treatment in overweight adults with insulin pump‐treated type 1 diabetes (T1D), focusing on changes in body composition and dimensions, and to evaluate changes in food intake to identify potential dietary drivers of liraglutide‐associated weight loss. Materials and methods A 26‐week randomized placebo‐controlled study was conducted to investigate the efficacy and safety of liraglutide 1.8 mg daily in 44 overweight adults with insulin pump‐treated T1D and glucose levels above target, and demonstrated significant glycated haemoglobin (HbA1c)‐ and body weight‐reducing effects. For secondary outcome analysis, dual X‐ray absorptiometry scans were completed at Weeks 0 and 26, and questionnaire‐based food frequency recordings were obtained at Weeks 0, 13 and 26 to characterize liraglutide‐induced changes in body composition and food intake. Results Total fat and lean body mass decreased in liraglutide‐treated participants (fat mass −4.6 kg [95% confidence interval {CI} −5.7; −3.5], P   〈  0.001; lean mass −2.5 kg [95% CI −3.2;‐1.7], P   〈  0.001), but remained stable in placebo‐treated participants (fat mass −0.3 kg [95% CI −1.3;0.8], P  = 0.604; lean mass 0.0 kg [95% CI −0.7;0.7]; P  = 0.965 [between‐group P values 〈 0.001]). Participants reduced their energy intake numerically more in the liraglutide arm (−1.1 MJ [95% CI −2.0;‐0.02] , P  = 0.02) than in the placebo arm (−0.9 MJ [95% CI −2.0;0.1], P  = 0.22), but the between‐group difference was statistically insignificant ( P  = 0.42). However, energy derived from added sugars decreased by 27% in the liraglutide arm compared with an increase of 14% in the placebo arm ( P  = 0.004). Conclusions Liraglutide lowered fat and lean body mass compared with placebo. Further, liraglutide reduced intake of added sugars. However, no significant difference in total daily energy intake was detected between liraglutide‐ and placebo‐treated participants.
    Type of Medium: Online Resource
    ISSN: 1462-8902 , 1463-1326
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2004918-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...